Moderna Inc (NQ: MRNA )
150.88 +1.46 (+0.98%) Streaming Delayed Price Updated: 4:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Press Releases about Moderna Inc
Development of Novel Innovative Diagnostic tests Generating Huge Revenue Opportunity for Global Blood Testing Market
February 16, 2022
Palm Beach, FL – February 16, 2022 – FinancialNewsMedia.com News Commentary – The global blood testing market has grown during the pandemic and is expected to continue to rise in the coming years....
Moderna and ROVI Expand Long-term Collaboration for the Manufacture of MRNA Medicines Over the Next Ten Years
February 16, 2022
Long-term agreement includes a series of investments to acquire new equipment and adapt the present ROVI drug product fill-finish facilities and production lines in Spain CAMBRIDGE, MA and MADRID,...
Moderna Announces Plan to Expand Footprint in Asia with Four Additional Subsidiaries
February 15, 2022
Announcement reinforces Moderna's commitment to Asia and vision as a global commercial enterprise New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong; providing local...
Moderna Chief Technical Operations and Quality Officer Juan Andres Elected to National Academy of Engineering
February 09, 2022
CAMBRIDGE, MA / ACCESSWIRE / February 9, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Juan Andres, Chief...
Moderna Announces New Supply Agreement with Colombia for Additional 10.8 Million Doses of Moderna's COVID-19 Vaccine
February 08, 2022
CAMBRIDGE, MA / ACCESSWIRE / February 8, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced a new supply agreement...
Moderna to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 24, 2022
February 03, 2022
CAMBRIDGE, MA / ACCESSWIRE / February 3, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live...
Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose SPIKEVAX has received approval by regulators in more than 70...
Exposures COVID-19 Product Safety
IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology
January 27, 2022
Phase 1 trial aims to build on response seen in proof-of-concept trial CAMBRIDGE, MA and NEW YORK, NY / ACCESSWIRE / January 27, 2022 / IAVI, the nonprofit scientific research organization, and...
Moderna Announces First Participant Dosed in Phase 2 Study of Omicron-Specific Booster Candidate and Publication of Data on Booster Durability Against Omicron Variant
January 26, 2022
Phase 2 study of Omicron-specific booster candidate (mRNA-1273.529) will include two cohorts: one including participants who received the two-dose primary series of mRNA-1273 and another including...
Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update
January 10, 2022
807 million doses of Moderna's COVID-19 vaccine shipped globally in 2021; approximately 25% of those doses shipped to low- and middle-income countries Product sales for 2021 approximately $17.5 billion...
Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
January 10, 2022
Collaboration will combine Carisma's engineered macrophage technology with Moderna's mRNA and LNP technologies to generate and develop in vivo CAR-M therapeutics Multi-year research collaboration...
Moderna Announces First Participant Dosed in Phase 1 Study of its mRNA Epstein-Barr Virus (EBV) Vaccine
January 05, 2022
Moderna expects to enroll approximately 270 participants in the U.S. EBV is a major cause of infectious mononucleosis, which can debilitate patients for weeks to months; there is no approved vaccine to...
Moderna to Present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference
January 04, 2022
CAMBRIDGE, MA / ACCESSWIRE/ January 4, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel...
Moderna to Provide Business and Pipeline Updates at the 2022 J.P. Morgan Healthcare Conference
January 03, 2022
CAMBRIDGE, MA / ACCESSWIRE / January 3, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that CEO Stéphane Bancel...
Moderna Announces Supply Agreement with South Korea for Additional 20 Million Doses of Moderna’s COVID-19 Vaccine or Updated Booster Candidate in 2022
December 27, 2021
Agreement includes 15 million doses for delivery in the third quarter of 2022 and 5 million doses for delivery in the fourth quarter of 2022 CAMBRIDGE, MA / ACCESSWIRE / December 27, 2021 / Moderna,...
Moderna Announces Switzerland Exercises its Option to Purchase Seven Million Additional Doses of Moderna's COVID-19 Booster Vaccine in 2022
December 27, 2021
Total of 27.5 million doses ordered by the Swiss Federal Government to date CAMBRIDGE, MA / ACCESSWIRE / December 27, 2021 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger...
Moderna Announces Preliminary Booster Data and Updates Strategy to Address Omicron Variant
December 20, 2021
Moderna and Australia Announce Collaboration to Bring mRNA Manufacturing to Australia
December 13, 2021
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective
December 07, 2021
FN Media Group Presents USA News Group News Commentary Vancouver, BC – December 7, 2021 – USA News Group – Despite a level of panic that JP Morgan has already downplayed in its 2022 forecasts, the...
Moderna to Present at Upcoming Investor Conferences in December 2021
November 22, 2021
Moderna Tops BioSpace’s 2022 Best Places to Work Ranking in Large Employer Category
November 17, 2021
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following